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Abstract
Dendritic cells (DCs) regulate innate and acquired immunity through their roles as antigen-presenting cells. Specific subsets
of mature DCs, including monocyte-derived and lymphoid-derived DCs, can be distinguished based on distinct
immunophenotypes and functional properties. The leukocyte integrin, CD11c, is considered a specific marker for DCs
and it is expressed by all DC subsets. We created a strain of mice in which DCs and their progenitors could be lineage traced
based on activity of the CD11c proximal promoter. Surprisingly, we observed levels of CD11c promoter activity that were
similar in DCs and in other mature leukocytes, including monocytes, granulocytes, and lymphocytes. We sought to identify
DNA elements and transcription factors that regulate DC-associated expression of CD11c. The ets transcription factor, PU.1,
is a key regulator of DC development, and expression of PU.1 varies in different DC subsets. GM-CSF increased monocyte-
derived DCs in mice and from mouse bone marrow cultured in vitro, but it did not increase CD8+ lymphoid-derived DCs or
B220+ plasmacytoid DCs. FLT3L increased both monocyte-derived DCs and lymphoid-derived DCs from mouse bone
marrow cultured in vitro. GM-CSF increased the 5.3 Kb CD11c proximal promoter activity in monocyte-derived DCs and
CD8+ lymphoid-derived DCs, but not in B220+ plasmacytoid DCs. In contrast, FLT3L increased the CD11c proximal promoter
activity in both monocyte-derived DCs and B220+ plasmacytoid DCs. We used shRNA gene knockdown and chromatin
immunoprecipitation to demonstrate that PU.1 is required for the effects of GM-CSF or FLT3L on monocyte-derived DCs. We
conclude that both GM-CSF and FLT3L act through PU.1 to activate the 5.3 Kb CD11c proximal promoter in DCs and to
induce differentiation of monocyte-derived DCs. We also confirm that the CD11c proximal promoter is not sufficient to
direct lineage specificity of CD11c expression, and that additional DNA elements are required for lineage-specific CD11c
expression.
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Introduction
Dendritic cells (DCs) are bone marrow-derived cells that play
crucial roles in regulating and integrating innate and adaptive
immune responses. DCs sample the environment, recognize
invading pathogens through pattern recognition Toll-like recep-
tors (TLRs), and initiate protective T cell responses by presenting
antigens to lymphocytes. Because of their highly developed antigen
presenting capacity, DCs have drawn attention for use in cell
therapy [1,2]. DCs are a heterogeneous group of cells that have
been classified into distinct subsets, primarily based on patterns of
cell surface antigen expression. The integrin aL chain, CD11c, is
considered relatively specific for DCs. CD11c is expressed on all
mature DC subsets in mouse, and its expression increases as DCs
mature from DC progenitors. Subsets of mature DCs in blood and
the lymphatic system include conventional DCs (cDCs;
CD11c+CD42CD8+CD11b2MHCII+, or
CD11c+CD4+CD82CD11b2MHCII+), plasmacytoid DCs (pDCs;
CD11c+B220+Ly6C+), and monocyte-derived DCs
(CD11c+CD11b+CD82CD42MHCII+) [3,4,5].
Differentiation of DCs from hematopoietic progenitor cells
depends on the activity of cytokines, including FLT3L (FMS-
related tyrosine kinase 3 ligand) and GM-CSF (granulocyte-
monocyte colony stimulating factor). Mouse hematopoietic pro-
genitor cells cultured with FLT3L generate all cDC subsets and
pDCs [6,7], and mice deficient for Flt3l have markedly reduced
numbers of cDCs and pDCs [8]. GM-CSF stimulates cultured
bone marrow cells to differentiate into monocyte-derived DCs
[9,10], but GM-CSF is not essential for DC development in the
steady state, as mice lacking the GM-CSF receptor (GM-CSFR)
have only slightly reduced numbers of DCs [11].
DC development also depends on transcription factors that
mediate extracellular cues from cytokines and their cognate
receptors. For example, interferon regulatory factor 8 (IRF-8) is
essential for the development of CD8+ cDCs and pDCs [12,13],
while IRF-4 deficiency in mice is associated with a marked
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reduction in CD82CD4+ cDCs [14,15]. The E protein, E2-2,
controls DC progenitor diversion to pDCs, as it is abundantly
expressed by pDCs and is required for pDC lineage specification
[16,17]. Conditional deletion in the hematopoietic compartment
of the ets transcription factor, PU.1, blocks development of both
cDC and pDC subsets [18]. PU.1 expression is high in early DC
progenitors and cDCs, but remains low in pDCs [3,4]. PU.1
controls the expression of FLT3 and GM-CSFR on progenitor
cells, but the mechanism by which it regulates DC lineage fate
choice remains to be elucidated.
In this study, we used lineage fate mapping to examine activity
of the CD11c proximal promoter under steady state conditions,
and in response to GM-CSF induction in vivo and ex vivo. Although
CD11c is considered relatively specific for DCs, we found that the
5.3 Kb CD11c proximal promoter is active in about 30% cells of
myeloid and lymphoid cells from bone marrow, spleen and
peripheral blood. Unexpectedly, CD11c promoter activity was
only slightly higher in DCs than in other hematopoietic lineages.
Growth of mouse bone marrow cells in the presence of GM-CSF
or FLT3L induced monocyte-derived DC differentiation, and
stimulated CD11c promoter activity in nearly 90% of DCs.
Similarly, treatment of mice with GM-CSF markedly increased
activity of the CD11c proximal promoter in both CD8a+ and
CD8a2 cDCs in spleen, but not in B220+ pDC subsets or other
hematopoietic lineages. Chromatin immunoprecipitation (ChIP)
demonstrated that PU.1 and IRF-4, which are known to be
essential for DC development, bound DNA elements within the
5.3 kb CD11c proximal promoter. Expression of these transcrip-
tion factors increased in response to GM-CSF or FLT3L-induced
DC differentiation. shRNA-mediated knock down of PU.1 in
cultured bone marrow cells inhibited GM-CSF or FLT3L-induced
monocyte-derived DC differentiation and reduced CD11c pro-
moter activity in response to these cytokines. In mouse spleen,
expression of Irf-4 is maintained at high level only in CD8a2CD4+
cDCs. Thus, GM-CSF or FLT3L activates the 5.3 kb CD11c
proximal promoter through synergy with essential DC transcrip-
tion factors, including PU.1 and IRF-4, whose expression are also
induced by GM-CSF or FLT3L signaling during differentiation of
cultured monocyte-derived DCs. Although administration of GM-
CSF in mice did not promote differentiation of CD8+ cDCs in
spleen, it was sufficient to CD11c promoter activity in both CD8+
and CD82 cDCs, most likely through the up-regulation of PU.1 in
these cells. This suggests that additional promoter or enhancer
elements, together with other transcription factors, account for the
CD11c expression in B220+ pDC subsets in spleen, and its lineage-
specific expression pattern exclusively in DCs.
Results
The CD11c Proximal Promoter Controlled GFP Expression
cannot be Detected in the Majority of DC Subsets from
the CD11c-Cre Mice
CD11c is considered a relatively specific marker of DCs, and
CD11c promoter-driven expression of Cre recombinase has been
used to inactivate genes in DCs. Stranges, et al. used a 5.3 kb
genomic DNA fragment that includes the mouse CD11c proximal
promoter to drive expression of both Cre recombinase and
enhanced green fluorescent protein (GFP); because GFP is co-
transcribed with Cre from the CD11c promoter, the intensity of
green fluorescence should indicate the specificity and efficacy of
the CD11c promoter. Among several transgenic mouse strains,
strain 4097 exhibited the highest level of GFP in CD11c+ DCs
[19]. However, even in CD11c-Cre mouse strain 4097, the GFP
expression in lymph node CD11c+ DCs was not markedly higher
than non-transgenic littermate controls, so that there was a
substantial portion of GFP2CD11c+ DCs from the CD11c-Cre
mice that overlapped with the GFP2CD11c+ DCs from the non-
transgenic littermate control mice. Therefore, the efficacy and
specificity of the CD11c-Cre transgene in the CD11c-Cre mouse
strain 4097 require better evaluation.
We analyzed GFP expression in DC and non-DC subsets of
cells from spleen, blood, and bone marrow of CD11c-Cre GFP
mouse train 4097; littermates that lacked CD11c-Cre GFP served
as negative controls. The percentage of GFP+ cells in total spleen
cells was less than 1% (Figure 1A). Because expression of GFP
reflects CD11c promoter activity, one would expect the percentage
of GFP+ cells to be higher in CD11c+ DC subsets than in the total
cell population or in other cell types. The percentage of GFP+ cells
in various CD11c2 populations, including myeloid cells (Gr1+), T-
lymphocytes (CD3+), B-lymphocytes (CD19+), and natural killer
(NK) cells (CD49b+) varied from 0.2% to 1.1% (Figure 1A); thus,
the percentage of GFP+ cells among these other cell types was not
significantly different from the percentage of GFP+ cells in
CD11c+ cells in spleen (0.4%). Stranges et. al. only characterized
DCs with the single surface marker CD11c [19]. It is possible that
the portion of GFP-expressing DCs was underestimated, and that
better defined DC populations with additional surface antigens
(B220 and Ly6C for pDCs; CD8, CD11b and MHC class II
(MHCII) for cDCs) could significantly increase the percentages of
GFP-expressing cells. Although CD8+ cDCs
(CD11c+CD8+CD11b2MHCII+) exhibited marked increase in
the percentage of GFP+ cells (16%), the majority of CD8+ cDCs
were still GFP2. Furthermore, neither the percentages of GFP+
cells nor the GFP level was significantly higher than non-DC cells
in spleen pDCs (CD11c+B220+Ly6C+), CD82 cDCs
(CD11c+CD82CD11b+MHCII+), MHCII+ activated DCs
(CD11c+MHCII+CD82), or in bone marrow derived DC
progenitors (Lineage2CD11c+CD11b2B2202CD43+) (Figure 1B).
Expression of CD11c increases and Ly6C decreases as DCs
mature. Based on expression of these antigens, splenic
CD82CD11c+ DCs can be divided into groups I, II, III, and
IV, which represent increasing states of differentiation [20].
Because CD11c expression increases during DC maturation, the
percentage of GFP+ cells should be expected to increase. However,
we observed no significant increase in the percentage of GFP+ cells
in group I compared to groups II, III, or IV (Figure 1C). GFP
expression was detected in only a small fraction of the CD11c+
DCs, and some CD11c2 cells contain comparable percentage of
GFP+ cells. We conclude that expression of CD11c-GFP
expression is not specific for CD11c+ DCs, and the CD11c
proximal promoter did not accurately recapitulate the expression
of native CD11c in mouse DC subsets.
Generation of Mice Bearing both CD11c-Cre and Rosa26
loxP-STOP-loxP
Because CD11c proximal promoter activity (i.e. CD11c-Cre-
GFP expression) did not reflect expression of native CD11c in
DCs, we utilized CD11c promoter-driven Cre recombinase
expression to lineage trace DCs. The similar strategy has been
used to examine gene activation/deletion restricted in DCs of
another CD11c-Cre transgenic mouse train [20]. We bred
CD11c-Cre mice to a mouse strain that bears the enhanced
yellow fluorescent protein (YFP) gene that was knocked-into a
locus immediately downstream of the endogenous Rosa26 gene
promoter and loxP-STOP-loxP sequences [20,21], as illustrated in
Figure 2A, B, C. Rosa26 is expressed in all tissues, and flow
cytometry can be used to detect YFP expression that is activated
by Cre-mediated deletion of the STOP sequence. Mice carrying
PU.1 and CD11c Expression in DCs
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both transgenes genes were identified by PCR on their genomic
DNA for the presence of CD11c-Cre construct (420 bps) and the
Rosa26 loxP-STOP-loxP (600 bps) (Figure 2D).
YFP Expression occurs in all Lineages of Hematopoietic
Cells from Mice Bearing CD11c-Cre and Rosa26 loxP-
STOP-loxP
As illustrated in Figure 3A, YFP expression was observed in
about 30% of total spleen cells and 26% of peripheral blood
leukocytes. Because each of these hematopoietic organs contains
only a small percentage of CD11c+ DCs, the substantially higher
percentages of YFP+ cells indicates that CD11c-Cre must also be
active in non-DC lineages. In fact, approximately 30% of Gr1+
granulocytes, B220+ B-lymphocytes, and CD3+ T-lymphocytes in
spleen express YFP (Figure 3A). Unexpectedly, nearly half of
CD11c+ DCs were YFP negative. Analysis of various DC subsets
with additional cell surface markers demonstrated significant
increases of YFP+ cells in CD8+ cDCs
(CD11c+CD8+CD11b2MHCII+) (65%), CD82 cDCs
(CD11c+CD82CD11b+MHCII+) (52%), pDCs
(CD11c+B220+Ly6C+) (48%), inactivated (CD11c+CD8+MHCII+)
(59%) and activated DCs (CD11c+CD82MHCII+) (58%). But
none of their percentages of YFP+ DCs were even close to 100%
(Figure 3B). CD11c expression increases during the maturation of
spleen DCs from stage I through II and III to stage IV and, as
expected, the percentage of YFP+ DCs increased from 32% to
58% as DCs differentiated from stage I through stage IV
Figure 1. CD11c-Cre mice have minimal GFP+ DCs in spleen. Flow cytometric analysis of CD11c-Cre mouse spleen cells for their GFP
expression in A) DCs, myeloid cells, T- and B-lymphocytes and natural killer (NK) cells. B) Flow cytometric analysis of the same mouse spleen cells for
GFP expression in different DC subsets including pDCs (CD11c+B220+CD82CD11b2Ly6C+), CD8+ DCs (CD11c+CD8+CD11b2MHCII+), CD82CD11b+ DCs
(CD11c+CD82CD11b+MHCII+), inactivated (CD11c+MHCII+CD8+) and activated DCs (CD11c+MHCII+CD82) and DC progenitors (Line-
age2CD11c+CD11b2B2202CD43+). C) Analysis of CD11b+ spleen cells for GFP expression during their maturation from group I (CD11c2Ly6Chi),
group II (CD11c2Ly6Clow), to group III (CD11c2Ly6C2), and group IV (CD11c+Ly6C2).
doi:10.1371/journal.pone.0052141.g001
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(Figure 3C), however, even the most mature DCs, i.e. stage IV,
were not 100% YFP positive. This finding demonstrates that
CD11c proximal promoter-driven Cre-mediated recombination
occurs in all hematopoietic lineages. Although there was higher
percentage of YFP+ cells in CD11c+ DCs, not all CD11c+ DCs
were YFP+. This finding is in great contrast to the observation
from Boris Reizis group, where in a different strain of CD11c-Cre
transgenic mouse, the percentages of YFP+ cells ranges from 86%
to 97% in DC subsets, and were from 0.3% to 12% in nonDC cells
[20]. Thus, the 5.3 Kb CD11c proximal promoter activity is
neither fully sensitive nor specific for detection of DCs.
YFP Expression Occurs in Hematopoietic Stem and
Progenitor Cells from Mice Bearing CD11c-Cre and
Rosa26 loxP-STOP-loxP
Bone marrow derived DC progenitors express low levels of
CD11c, but hematopoietic stem cells (HSCs), myeloid, and
lymphoid progenitor cells do not express CD11c [22]. If
expression of the CD11c-Cre transgene mimics expression of
endogenous CD11c, lineage negative (Lin2) stem and progenitor
cells should be CD11c2 and YFP2. Surprisingly, nearly a quarter
of Lin- bone marrow cells expressed YFP (Figure 4A and 4B).
Furthermore, more than one quarter of HSCs (Lin2 c-Kit+ and
Sca1+, LSK) and myeloid progenitor cells (Lin2 c-Kit+ Sca12, LK)
expressed YFP (Figure 4A). Bone marrow DC progenitor cells that
are Lin2, Sca12, Flt3+ and Mcsfr+, including MDP (c-Kit+FccII/
III+) and CDP (c-Kit2FccII/III+), demonstrated similar percent-
ages of YFP+ cells (Figure 4B). Thus, the 5.3 Kb CD11c proximal
promoter is active under steady state conditions in a significant
portion of HSCs and progenitor cells.
GM-CSF and FLT3L Induced a Significant Increase in
Transgenic 5.3 Kb CD11c Proximal Promoter Activity in
Cultured Bone Marrow Derived DC Subsets
Cytokine signaling plays crucial roles in DC development. GM-
CSF drives the formation of DCs from cultured mouse bone
marrow cells or human peripheral monocytes [9,10], and GM-
CSF promotes monocyte derived DC development under inflam-
matory conditions [9–11]. FLT3L supports the development of
DCs in vitro [7,8,23], and FLT3L signaling is required for in vivo
steady-state development of various mouse DC subsets [8]. To test
whether the 5.3 Kb CD11c proximal promoter is responsive to
GM-CSF or FLT3L signaling, bone marrow cells from mice
bearing CD11c-Cre and Rosa26 loxP-STOP-loxP were cultured
in vitro with GM-CSF or FLT3L to induce DC differentiation.
After six days growth in GM-CSF, the majority of the bone
marrow cells were CD11b+, and CD11c+ cells increased to 7% of
total cultured bone marrow cells (Figure 5A). The percentage of
YFP+ cells in CD11b+CD11c+ DCs was 50%, which was markedly
higher than that in total cultured cells or CD11b+CD11c2 non-
DC cells (Figure 5A). The percentage of CD11c+ cells increased
further to 71% after eleven days of growth in GM-CSF (Figure 5B).
Both the intensity of YFP expression and the percentage of YFP+
CD11c+CD11b+ DCs increased from 50% on day 6 to nearly 90%
on day 11 (Figure 5B). In FLT3L treated cell culture, however, the
CD11b+ cells were less than 20%, and the CD11c+ cells increased
to more than 12% of total cultured bone marrow cells after six
days induction by FLT3L. Consistent with previous reports,
FLT3L induced an additional population of
CD11c+CD11b2B220+ pDCs (Figure 5C) [23]. Similarly, the
percentage of YFP+ cells in FLT3L treated CD11b+CD11c+ DCs
was 44%, which was higher than that in CD11c+CD11b2B220+
pDCs or CD11b+CD11c2 non-DC cells (Figure 5C). Once again,
the percentage of CD11c+ cells increased further to 54% after
eleven days of treatment of FLT3L (Figure 5D). Both the intensity
of YFP expression and the percentage of YFP+ DCs increased
from 44% on day 6 to nearly 90% on day 11. The YFP+
CD11c+CD11b2 pDCs increased from 36% on day 6 to 58% on
day 11 (Figure 5D). Thus, the 5.3 Kb CD11c proximal promoter
is highly responsive to both GM-CSF and FLT3L signaling during
DC development in cultured mouse bone marrow cells.
GM-CSF Activated the Transgenic 5.3 Kb CD11c Proximal
Promoter in CD8+ and CD82 cDCs, but not pDCs, During
the Induced Differentiation of DCs in Mouse Spleen
GM-CSF stimulates DC differentiation in culture, but it is not
essential for the steady-state DC differentiation in vivo [11]. GM-
CSF has a greater role in production of monocyte-derived DCs
Figure 2. Generation of mice bearing both CD11c-Cre and Rosa26 loxP-STOP-loxP YFP. Diagrams show A) the construct of loxP (triangles)
flanked transcription stop signal sequence (SA) followed by YFP under the control of Rosa26 locus; and B) the 5.3 kb CD11c proximal promoter
controlled Cre recombinase followed by IRES and GFP. C) the diagram demonstrates the breeding strategy of generating mice carrying both CD11c-
Cre and Rosa26 loxP-STOP-loxP. D) PCR on genomic DNA from offspring mice of the breeding pairs in C. Mice carrying both CD11c-Cre and Rosa26
loxP-STOP-loxP demonstrate both the 420 bp Cre product and the 600 bp YFP product.
doi:10.1371/journal.pone.0052141.g002
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than in other DC subsets. To test whether GM-CSF can activate
the 5.3 Kb CD11c proximal promoter in vivo, CD11c-Cre and
Rosa26 loxP-STOP-loxP mice were injected with GM-CSF, or
saline control. Flow cytometric analysis of cells harvested 48 hours
after injection demonstrated that saline injection did not change
the percentage of YFP+ spleen cells in DCs, myeloid or lymphoid
cells, and the percentages of the YFP+ cells were comparable to
uninjected mice in Figure 3 (data not shown). As shown in
Figure 6A, injection of GM-CSF significantly increased the
percentage and the total number of CD11c+ DCs in spleen.
There was a significant increase in the percentage of YFP+ cells in
CD11c+ DCs, a slight increase in Gr1+ myeloid cells, and a mild
decrease in B220+ B-lymphocytes (Figure 6A). As shown in
Figure 6B, the CD11c+CD11b+CD82MHCII+ cDCs represented
the majority of the increased DCs stimulated by GM-CSF in total
spleen cells. Similar to the observation in cultured cells, mice
injected with GM-CSF exhibited a substantial increase in the
percentage of CD82CD11b+ DCs in spleen and increased the
percentage of YFP+ cells among this population (compare
Figure 6B to Figure 3B). GM-CSF administration did not increase
the percentage of CD11c+CD11b2CD8+MHCII+ cDCs,
CD11c+CD8+MHCII+ inactiveated or CD11c+CD82MHCII+
activated DCs, but it did markedly increased the percentage of
YFP+ cells among these splenic DC subsets (Figure 6B). There was
no increase either in the percentage of CD11c+B220+pLy6C+
pDCs, or in the percentage that were YFP+ (Figure 6B). In
addition, the most mature CD11b+Ly6C2CD11chi DCs in spleen
demonstrated nearly 90% YFP+ cells, as shown in Figure 6C.
Thus, the 5.3 Kb CD11c proximal promoter, as measured by YFP
activity, is highly responsive to GM-CSF in both CD82CD11b+
Figure 3. CD11c-Cre mediated recombination to activate YFP expression in spleen cells. Flow cytometric analysis of spleen cells from
mice bearing both CD11c-Cre and Rosa26 loxP-STOP-loxP for the Cre activated YFP expression in A) various lineages including CD11c+ DCs, Gr1+
myeloid cells, B220+ B- and CD3+ T-lymphocytes, and in B) DC subsets including CD8+ DCs, CD82CD11b+ DCs, pDCs, inactivated and activated DCs.
C) Analysis of YFP expression in CD11b+ DCs during their maturation from group I to group IV.
doi:10.1371/journal.pone.0052141.g003
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and CD8+CD11b2 cDCs during GM-CSF induced DC differen-
tiation in vivo, but not in pDCs.
Cis-regulatory Elements on 5.3 Kb CD11c Proximal
Promoter Contain Motifs that are Bound by Crucial DC
Transcription factors During Cytokine Induced
Differentiation
The increased percentage of YFP+ DCs suggests that the 5.3 Kb
CD11c proximal promoter contains cis-elements that are respon-
sive to GM-CSF and FLT3L signaling. Alignment of a 5.3 kb
DNA sequence upstream of the CD11c transcription start site
(TSS) among mammalian species identified an evolutionarily
conserved region with about 2 kb that spans the TSS (Figure 7A).
Chromatin immunoprecipitation (ChIP) followed by high
throughput deep sequencing (ChIP-seq) on cell lines revealed
potential transcription factor binding sites in this conserved
promoter region (Figure 7A), including IRF-4 and PU.1, both of
which are known to be crucial for the development of DCs, B-
lymphocytes and myeloid cells.
Bone marrow cells were cultured in vitro with GM-CSF or
FLT3L for 7 days and analyzed by ChIP assay. As shown in
Figure 7B, both Irf-4 and Pu.1 bound the region of the CD11c
proximal promoter 2 kb upstream of the TSS in response to GM-
CSF (Figure 7B) or FLT3L (data not shown). Furthermore, the
mRNA levels of Irf-4 and Pu.1 in bone marrow cells cultured with
GM-CSF or FLT3L increased up to two fold, compared to the
same cells in the absence of GM-CSF or FLT3L (Figure 7C). Irf-4
expression is high only in CD82CD4+ cDCs, and is essential for
their development. PU.1 expression is high in both DC
progenitors and mature cDCs, but low in pDCs. Coincidentally,
GM-CSF-induced activation of the 5.3 Kb CD11c proximal
promoter occurs in CD8+ and CD82CD11b+ cDCs, but not in
pDCs. This suggests that GM-CSF-induced Pu.1 expression in
cDCs is required for activation of CD11c proximal promoter. To
test this hypothesis, bone marrow cells were transduced with
Figure 4. CD11c-Cre mediated recombination to activate YFP expression in mouse bone marrow hematopoietic stem and
progenitor cells. Flow cytometric analysis of bone marrow cells from mice bearing both CD11c-Cre and Rosa26 loxP-STOP-loxP for YFP expression
in A) lineage negative cells, early myeloid progenitors (LK), stem cells (LSK) and CMPs, GMPs, MEPs; and in B) DC progenitor cells including MDPs and
CDPs.
doi:10.1371/journal.pone.0052141.g004
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retrovirus containing shRNA specifically against Pu.1 or scram-
bled control shRNA. Immunoblotting on protein extracts from
cultured bone marrow cells demonstrated the near complete loss of
Pu.1 protein expression suppressed by shRNA specifically against
Pu.1 gene, but not by scrambled control shRNA (Figure 7D). As
shown in Figure 7E–7F, Pu.1 knock-down markedly inhibited
GM-CSF (Figure 7E) or FLT3L-induced (Figure 7F) differentia-
tion of CD11c+ monocyte-derived DCs and greatly reduced the
percentage of YFP+ DCs, compared to control cells transduced
with scrambled shRNA. Pu.1 knockdown also reduced FLT3L-
induced differentiation of pDCs and the percentage of YFP+ pDCs
(Figure 7F). To summarize, the 5.3 Kb CD11c proximal promoter
contains Irf-4 and Pu.1 binding elements that are responsive to
GM-CSF or FLT3L-induced DC differentiation in vivo and ex vivo,
Figure 5. CD11c-Cre mediated recombination to activate YFP expression in mouse bone marrow cells cultured with GM-CSF or
FLT3L. Flow cytometric analysis of bone marrow cells from mice bearing both CD11c-Cre and Rosa26 loxP-STOP-loxP for their YFP expression in
CD11c+ and CD11c2 cells after cultured with GM-CSF or FLT3L for 6 days A) and C), and for 11 days B) and D), respectively.
doi:10.1371/journal.pone.0052141.g005
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Irf-4 and Pu.1 expression increase in response to GM-CSF
treatment, and Pu.1 is essential for both GM-CSF and FLT3L-
induced CD11c expression in monocyte-derived DCs in culture.
Thus, Pu.1 appears to be the key regulator that controls CD11c
expression in both CD8+ and CD82 lymphoid resident cDCs.
Discussion
The leukocyte integrin, CD11c, is expressed by DCs and is
considered to be a relatively specific marker of this lineage. In this
study we demonstrated that expression of GFP driven by the
5.3 kb proximal promoter of mouse CD11c did not accurately
reflect expression of native CD11c. We generated mice that are
transgenic for both CD11c-Cre and Rosa26-loxP-STOP-loxP
YFP, which can trace activation of the CD11c proximal promoter
during DC differentiation. We found that the CD11c promoter
was also active in HSCs, hematopoietic progenitor cells, and in all
categories of mature leukocytes. Thus, the CD11c proximal
promoter is neither sufficient nor specific for driving CD11c
expression in DCs, and we conclude that additional promoter or
enhancer regions of CD11c must be required to control its specific
expression pattern in DCs. Treatment of bone marrow cells in vitro
with GM-CSF or FLT3L increased CD11c expression in
monocyte-derived (CD11b+) DCs. In vivo, GM-CSF activated the
CD11c promoter in CD11b+ DCs and in CD8+ DCs, but not in
B220+ pDCs. We showed that the transcription factors, Irf-4 and
Pu.1, bound to the CD11c proximal promoter, and that Pu.1
knock down reduced GM-CSF or FLT3L-induced CD11c
Figure 6. CD11c-Cre mediated recombination to activate YFP expression in spleen cells after GM-CSF administration in mice. Mice
bearing both CD11c2Cre and Rosa26 loxP-STOP-loxP were injected with GM-CSF followed by flow cytometric analysis of their spleen cells for YFP
expression in A) different lineages including DCs, myeloid cells, B- and T-lymphocytes, and in B) DC subsets including CD8+ DCs, CD82CD11b+ DCs
and pDCs. C) Analysis of YFP expression in CD11b+ DCs during their maturation from group I to group IV.
doi:10.1371/journal.pone.0052141.g006
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promoter activation. Together with the observation that expres-
sion of Pu.1 is high in CD8+ and CD11b+ cDCs, but low in B220+
pDCs, we conclude that high level expression of Pu.1 is essential
for the control of CD11c expression in CD11b+ and in CD8+
cDCs.
The CD11c gene encodes the integrin aL chain, a leukocyte cell
surface antigen that is routinely used as a specific marker of DCs,
but the cis-regulatory elements that restrict its expression to DCs
have not been identified. We used two different approaches to
examine CD11c promoter activity in mouse DCs and other blood
cells. Expression of GFP directly reflects CD11c promoter activity
at the time of analysis. In contrast, Cre activation of YFP
expression reflects a cumulative effect of CD11c activity during the
development of particular lineages. Expression of YFP by HSCs
and progenitors indicates that the CD11c promoter is active in
immature hematopoietic cells. Thus, Cre activation of YFP reflects
the derivation of hematopoietic cells. It may also serve as a more
sensitive indicator of CD11c promoter activity than the GFP
model.
Growth and differentiation of DCs depend on signals from
extracellular growth factors, including GM-CSF and FLT3L. The
transcription factors, IRF-4 and PU.1, are critical for development
of DCs, i.e. PU.1 is required for the development of all DC subsets,
while IRF-4 is essential for CD82CD4+ lymphoid resident cDCs
in spleen. Our findings demonstrated that expression of transcrip-
tion factors PU.1 and IRF-4 is induced by GM-CSF or FLT3L.
Expression of CD11c, the DC specific target gene of both Pu.1
and Irf-4, is rapidly increased in response to GM-CSF or FLT3L
induction in mouse bone marrow cells. This demonstrates that the
coordination of extrinsic GM-CSF or FLT3L signal with the
transcriptional programming by PU.1 and IRF-4 in DCs
contributes to the DC specific gene expression and committed
DC differentiation.
GM-CSF induces development of monocyte-derived DCs in
culture, while FLT3L induces the differentiation of both mono-
cyte-derived and lymphocyte-derived DCs [8]. We showed that
monocyte-derived DCs increased significantly in GM-CSF-treated
mice. It appears that PU.1 is the key transcription factor mediating
the GM-CSF or FLT3L induced up-regulation of CD11c in cDCs,
because PU.1 knockdown markedly reduced CD11c activation in
response to these cytokines. PU.1 knockdown demonstrated that
PU.1 is also required for FLT3L induced CD11c expression in
pDCs. GM-CSF also induced activation of CD11c in CD8+ cDCs,
even though GM-CSF alone is not sufficient to promote the
differentiation of CD8+ cDCs. Thus, the molecular mechanism on
how CD11c gene is activated by GM-CSF signaling in CD8+ DCs
remains to be elucidated. The findings that GM-CSF did not
further activate CD11c expression in pDCs, and that GM-CSF
induction or Pu.1 expression cannot promote CD8+ DC
differentiation, indicate that different transcription factors are
responsive to the same extracellular signaling in specific DC
subsets, and that specific combinations of transcription factors
contribute to terminal cell differentiation of these different DC
subsets.
Materials and Methods
Mice, Bone Marrow Cell Culture and Retroviral Gene
Transfer
CD11c-Cre mice (C57BL/6J-Tg(Itgax-cre,-EGFP)4097Ach/J)
and Rosa26 loxP-STOP-loxP YFP mice (B6.129X1-Gt(ROSA)26-
Sortm1(EYFP)Cos/J) were purchased from The Jackson Labora-
tory (Bar Harbor, ME). To generate mice carrying both the
transgenes, CD11c-Cre mice were bred with Rosa26 loxP-STOP-
loxP mice and offspring pups were subject to genomic PCR for
genotyping. Mice that carry one allele of the CD11c-Cre and one
allele of the Rosa26 loxP-STOP-loxP were selected for subsequent
analysis. Six to twelve week old mice were used for all studies. All
animal studies were approved by the University of Massachusetts
Institutional Animal Care and Utilization Committee.
For bone marrow cell culture, bone marrow cells were flushed
from femora and pelves of indicated mice with RPMI (American
Type Culture Collection [ATCC] Manassas, VA) plus 10% fetal
bovine serum (FBS; Invitrogen, Carlsbad, California). NIH/3T3
and HEK293 (ATCC, Manassas, VA) cells were maintained in
DMEM (Invitrogen Corp., Carlsbad, CA) with 10% FBS. Bone
marrow cells were grown in RPMI/10% FBS with GM-CSF at
30 ng/mL, or FLT3L at 100 ng/mL for 6 or 11 days. GM-CSF
and FLT3L were purchased from PeproTech Inc. (Rocky Hill,
NJ). For in vivo administration, mice were intraperitoneally
injected with GM-CSF at 100 ng/gram body weight and cells
were collected 48 hours later for analysis. For retroviral shRNA
transduction, bone marrow cells were transduced with retroviruses
containing shRNA against Pu.1 or scrambled control (Open
Biosystems Inc. Lafayette, CO) for 48 hours and grown in 2.5 mg
ml21 puromycin (Sigma-Aldrich, St. Louis, MO) for 3–5 days.
Flow Cytometry Analysis and Immunoblotting
Lineage staining of bone marrow and spleen was performed
with fluorescent conjugated antibodies against Gr1, CD11b, B220,
CD3e, Ter119, F4/80 and Mac3 (eBiosciences, San Diego, CA).
Other antibodies used for flow cytometry include: M-CSF-R,
Ly6C, c-kit, Flt3, Sca-1, CD34 and FccII/III (eBiosciences).
Antibodies against CD11c, CD19 and CD49b were purchased
from BD Biosciences (Franklin Lakes, NJ). Flow cytometry utilized
LSRII or FACSAria II, respectively (BD Biosciences). Flow
cytometry data were analyzed with Diva (BD Biosciences) and
FlowJo software (Tree Star Inc, Ashland, OR). Immunoblotting
was performed according to standard protocol. Antibodies against
PU.1 and b-Actin were purchased from SantaCruz Biotechnology
(Santa Cruz, CA).
Reverse Transcription and Real-Time, Quantitative PCR
Reverse Transcription was performed with New England
BioLabs DyNAmo cDNA synthesis kit, per manufacturer’s
protocol, with an Applied Biosystems thermal-cycler. Quantitative
Real-time PCR was performed with Qiagen real-time PCR master
kit with an Eppendorf real-time thermal-cycler.
Figure 7. CD11c proximal promoter contains binding sites for PU.1 and IRF-4, which are essential for GM-CSF or FLT3L-induced
CD11c activation. A) Diagram demonstrating the human 5.3 kb CD11c proximal promoter. Transcription factors binding to this region according
to ChIP-seq analysis of existing data are illustrated in the diagram. B) ChIP assays on cultured mouse bone marrow cells with GM-CSF for the binding
of Pu.1 and Irf-4 to the CD11c proximal promoter region. C) Quantitative PCR on reverse transcribed mRNA from mouse bone marrow cells cultured
with GM-CSF or FLT3L to evaluate expression of Pu.1 and Irf-4. Bone marrow cells from mice bearing both CD11c-Cre and Rosa26 loxP-STOP-loxP
were transduced with retrovirus carrying either scrambled control shRNA or shRNA against Pu.1 followed by puromycin selection of transduced cells.
Immunoblotting D) and Flow cytometric analysis of the transduced cells for the expression YFP in both CD11c+ and CD11c2 cells 11 days after
culturing with GM-CSF E), or FLT3L F).
doi:10.1371/journal.pone.0052141.g007
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Chromatin Immunoprecipitation (ChIP) Assays
Chromatin was immunoprecipitated with Pu.1 or Irf-4 antibody
(Santa Cruz Biotechnology, Inc.), and protein G sepharose beads
(Pierce Biotechnology, Inc. Rockford, IL). ChIP procedure was
performed according to manufacturer’s protocol (Pierce Biotech-
nology). PCR primers for PU.1: 59-ACAACTTCCCACCCT-
GACTG-39, 59-GGTTGTGAAGGTGTGGCTTT-39; IRF-4:
59-GCAGAGCAAGACCCTGTTTC-39, 59-CTGAGCATT-
GAAAGCAACCA-39.
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